Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
2(17%)
Results Posted
14%(1 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_3
2
17%
Ph early_phase_1
1
8%
Ph phase_1
1
8%
Ph not_applicable
1
8%
Ph phase_4
7
58%

Phase Distribution

2

Early Stage

0

Mid Stage

9

Late Stage

Phase Distribution12 total trials
Early Phase 1First-in-human
1(8.3%)
Phase 1Safety & dosage
1(8.3%)
Phase 3Large-scale testing
2(16.7%)
Phase 4Post-market surveillance
7(58.3%)
N/ANon-phased studies
1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

2

trials recruiting

Total Trials

12

all time

Status Distribution
Active(2)
Completed(7)
Terminated(2)
Other(1)

Detailed Status

Completed7
Terminated1
Active, not recruiting1
unknown1
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
2
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (8.3%)
Phase 11 (8.3%)
Phase 32 (16.7%)
Phase 47 (58.3%)
N/A1 (8.3%)

Trials by Status

terminated18%
completed758%
active_not_recruiting18%
unknown18%
withdrawn18%
recruiting18%

Recent Activity

2 active trials
Showing 5 of 12
active_not_recruitingearly_phase_1

Autonomic Determinants of POTS - Pilot1

NCT04050410
recruitingphase_1

Sympathetic Mechanisms in Obesity-Crossover Design

NCT05312892
completedphase_4

Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease

NCT01094769
completedphase_4

Moxonidine Effects on Neuropeptide Y

NCT05147753
completednot_applicable

Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women

NCT02355821
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT04050410Early Phase 1

Autonomic Determinants of POTS - Pilot1

Active Not Recruiting
NCT05312892Phase 1

Sympathetic Mechanisms in Obesity-Crossover Design

Recruiting
NCT01094769Phase 4

Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease

Completed
NCT05147753Phase 4

Moxonidine Effects on Neuropeptide Y

Completed
NCT02355821Not Applicable

Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women

Completed
NCT01567124Phase 4

Alleviating the Metabolic Side Effects of Antipsychotic Medications

Withdrawn
NCT01504321Phase 4

Polycystic Ovary Syndrome - Improving Outcomes

Completed
NCT01791699Phase 4

Moxonidine for Prevention of Post-ablation AFib Recurrences

Completed
NCT01138423Phase 4

Treatment of Adiposity Related hypErTension (TARGET)

Completed
NCT01360710Phase 4

The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension

Unknown
NCT00244504Phase 3

Moxonidine in Patients Undergoing Vascular Surgery

Terminated
NCT00160277Phase 3

Efficacy and Safety of Moxonidine in Indian Patients

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12